Izencitinib (example 1 [WO2016191524A1]) is described as a Janus kinase (JAK) inhibitor in INN proposed list 121 (of August 2019). It is example 1 in Theravance Biopharma's patent that claims JAK inhibitors for immunomodulatory potential [1
]. Review of Theravance's disclosed pipeline reveals one JAK inhibitor coded TD-8326 in their asthma program. However, until the chemical structure of TD-8326 is formally disclosed its relationship to patent example 1 and izencitinib remains speculative.